SJR 10 — Urges Congress to take certain actions relating to the therapeutic use of certain psychedelic compounds. (BDR R-801)

(ReprintedSenate withJoint amendmentsResolution adoptedNo. on April 17, 2025) FIRST REPRINT S.J.R.

1010–Senators SNguyen, ENATEStone; JOINTR ESOLUTION NO .

10–ENATORSDaly, NDoñate, GUYENFlores, ,Hansen, TONEOhrenschall ;and Scheible Joint Sponsors:

DAssemblymembers ALY,González, DOÑATEMoore, ,Nguyen, LORES,Carter, HANSENWatts; , HRENSCHALL AND SCHEIBLE FEBRUARY 26, 2025 ____________ JOINT SPONSORS :

AAnderson, SSEMBLYMEMBERSBrown-May, GConsidine, ONZÁLEZDalia, ,Dickman, MOORED’Silva, ,Gallant, NGray, GUYENHansen, ,Hibbetts, CARTERJackson, ,Karris, WOrentlicher ATTS;and Roth FILE NUMBER..........

A NDERSON , B ROWN -M AY, CONSIDINE , ALIA , ICKMAN , D’SILVA, GALLANT , GRAY, H ANSEN, HIBBETTS, ACKSON , KARRIS, ORENTLICHER AND ROTH ____________ Referred to Committee on Legislative Operations and Elections SUMMARY—Urges Congress to take certain actions relating to the therapeutic use of certain psychedelic compounds.

(BDR R-801) FISCAL NOTE:

Effect on Local Government:

No.

Effect on the State:

No.

~ EXPLANATION – Matter in bolded italics is new;

matter between brackets [omitted material] is material to be omitted.

and W HEREAS , Preliminary research has indicated that certain psychedelic compounds, including psilocybin, psilocin, N,N- dimethyltryptamine (DMT), ibogaine, mescaline and 3,4- methylenedioxymethamphetamine (MDMA), when administered in - *SJR10_R1* – 2 – controlled clinical settings, show promising therapeutic potential for treating various mental health conditions;

andandherapeutic potential for W HEREAS , The United States Food and Drug Administration has granted, in 2017, 2018 and 2019, respectively, MDMA-assisted therapy for PTSD, psilocybin therapy for treatment-resistant depression and psilocybin therapy for major depressive disorder Breakthrough Therapy designation, thereby acknowledging the potential of those treatments to offer substantial improvement over existing treatments and expediting their development and review;

and W HEREAS , Researchers at Stanford University demonstrated that ibogaine treatment led to significant improvements in veterans - 83rd Session (2025) – 2 – with traumatic brain injury and PTSD, with participants experiencing average reductions of 88 percent in symptoms of PTSD, of 87 percent in symptoms of depression and of 81 percent in symptoms of anxiety at their 1-month follow-up;

and W HEREAS , Clinical research has demonstrated significant potential for psychedelic compounds to address chronic pain conditions, with studies showing that the pulse administration of psilocybin reduced the frequency of cluster headache attacks by approximately 50 percent from baseline, from an average of 18.4 attacks to 9.8 attacks per week, and MDMA-assisted therapy produced significant reductions in the pain intensity, disability and overall pain severity of patients with PTSD with high baseline pain levels;

and W HEREAS , The National Defense Authorization Act for Fiscal Year 2024, Public Law 118-31, directed the Department of Defense to establish a process for service members to participate in clinical trials studying psychedelic compounds, including psilocybin and MDMA, for treating PTSD and traumatic brain injury, allocated $10,000,000 in funding and authorized partnerships with other - *SJR10_R1* – 3 – agencies and academic institutions, thereby demonstrating growing federal recognition of the potential of these treatments;

and - 83rd Session (2025) – 3 – W HEREAS , Clinical research demonstrates that psychedelic compounds like psilocybin and MDMA have a favorable safety profile when administered in controlled clinical settings with appropriate medical screening and supervision, with studies showing no lasting neuropsychological deficits, organ damage or serious adverse reactions and a significantly lower rate of adverse medical events compared to many current standard treatments;

and W HEREAS , Controlled substances classified in schedule I are subject to significant barriers to research, including more I are burdensome regulatory and bureaucratic hurdles than research of other controlled substances;

and - *SJR10_R1* – 4 – W HEREAS , Leading medical research institutions have established dedicated centers for psychedelic research, including the Johns Hopkins Center for Psychedelic and Consciousness Research, the Project on Psychedelics Law and Regulation at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, the University of California Berkeley Center for the Science of Psychedelics, the New York University Langone Health’s Center for Psychedelic Medicine, the Parsons Research Center for Psychedelic Healing at the Icahn School of Medicine at Mount Sinai, the Yale Program for Psychedelic Science, the University of Wisconsin-Madison Transdisciplinary Center for Research in Psychoactive Substances, the Stanford Psychedelic Science Group, the Massachusetts General Hospital Center for the Neuroscience of Psychedelics, the Charmaine and Gordon McGill Center for Psychedelic Research and Therapy at Dell Medical - 83rd Session (2025) – 4 – School at the University of Texas at Austin and the Washington University Program in Psychedelics Research;

now, therefore, be it R ESOLVED BY THE SSENATE ENATE AND ASSEMBLYA SSEMBLY OF THE STATE OF N EVADA , OINTLY , That the Nevada Legislature hereby urges the Congress of the United States and the appropriate federal agencies to:

Increase federal funding for research into the therapeutic applications of psychedelic compounds, particularly for treating mentalmen2.l healthEstablish conditions,aitiostreamlinedce substanceprocessordfor useaapproving disordersandin; and chronic pain;

2.conducting research with psychedelic compounds, while maintaining appropriate safety protocols and oversight;

Establish a streamlined process for approving and conducting research with psychedelic compounds, while maintaining appropriate safety protocols and oversight;

Establish legal protection against federal prosecution for individuals and entities complying with state and local law concerning the supervised adult use of psychedelic compounds and require states to enter research partnerships with the Attorney General under the Controlled Substances Act to study the public health outcomes of such state programs;

and be it further - *SJR10_R1* – 5 – R ESOLVED , That the Nevada Legislature supports expanded research into the therapeutic potential of psychedelic compounds at qualified research institutions within this State;

and be it further R ESOLVED , That the Secretary of the Senate prepare and transmit a copy of this resolution to the President of the United States, the Vice President of the United States as the presidingdpresiding officer of the Senate, the Speaker of the House of Representatives, each member of the Nevada Congressional Delegation, the Administrator of the United States Drug Enforcement Administration and the Director of the National Institutes of Health;

and be it further - 83rd Session (2025) – 5 – R ESOLVED , That this resolution becomes effective upon passage.

H~~~~~ 25 - *SJR10_R1*83rd Session (2025)